Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib (Q61446600)

From Wikidata

Jump to navigation Jump to search

scientific article published in PLoS ONE

edit

Language	Label	Description	Also known as
English	Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib	scientific article published in PLoS ONE

Statements

instance of

scholarly article

0 references

title

Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib (English)

0 references

author

Brian Czerniecki

series ordinal

5

object named as

Brian J Czerniecki

0 references

author name string

Loral E Showalter

series ordinal

1

0 references

Crystal Oechsle

series ordinal

2

0 references

Nirmala Ghimirey

series ordinal

3

0 references

Chase Steele

series ordinal

4

0 references

Gary K Koski

series ordinal

6

0 references

language of work or name

English

0 references

publication date

2019

0 references

published in

PLOS One

0 references

volume

14

0 references

issue

1

0 references

page(s)

e0210209

0 references

copyright license

Creative Commons Attribution 4.0 International

start time

18 January 2019

1 reference

stated in

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

describes a project that uses

ImageQuant

1 reference

stated in

Europe PubMed Central

retrieved

11 June 2022

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6338365/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

cites work

Receptor protein-tyrosine kinases and their signal transduction pathways

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure of the extracellular region of HER3 reveals an interdomain tether

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab versus lapatinib: the cardiac side of the story

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Projections of the cost of cancer care in the United States: 2010-2020.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance to BRAF-targeted therapy in melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T-helper-1-cell cytokines drive cancer into senescence

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiotoxicity of novel HER2-targeted therapies.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer treatment and survivorship statistics, 2014

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of lapatinib resistance in HER2-driven breast cancer.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30657766

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1371/JOURNAL.PONE.0210209

0 references

PMC publication ID

6338365

0 references

PubMed publication ID

30657766

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61446600&oldid=1888963912"